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ABSTRACT
Pueraria mirifica (PM) is a phytoestrogen-rich plant that was tested to establish if its phytosteroids could prevent 
estrogen dependent sarcopenia. The effect of PM on the estrogen levels, estrous cycle, toxicity, muscle mass, strength 
and endurance of extensor digitorum longus (EDL) and gastrocnemius muscles of ovariectomized rats was investigated. 
Adult female Wistar rats were divided into six groups: Sham-operated (SHAM); ovariectomized (OVX) fed with distilled 
water (PM0); OVX injected with 40 µg/kg estradiol benzoate (E40); (4-6) OVX fed with ethanolic extract of PM at doses 
of 50 (PM50), 500 (PM500) and 1000 (PM1000) mg/kg for 90 days. After treatment with all three doses of PM, no toxicity 
was detected to the hematopoietic system and liver function whereas the E40 group did show toxic effects. Treatment 
with 50 and 500 mg/kg of PM showed no effect on uterine hypertrophy and caused no arrest of the estrous cycle whereas 
treatment with estrogen and 1000 mg/kg of PM treatment did. The estrogen level, the cross sectional area of the EDL and 
the gastrocnemius muscle fiber strength and endurance were all significantly reduced in the PM0 group compared to that 
of the SHAM group (p<0.05) but were significantly increased in the E40, PM50, PM500 and PM1000 compared to that of 
the PM0 group (p<0.05). This indicated that the estrogenic activity of PM alleviated muscle atrophy and built up muscle 
strength and endurance. Thus, the 50 and 500 mg/kg of PM were suitable for treating estrogen dependent sarcopenia in 
ovariectomized rats.
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ABSTRAK
Pueraria mirifica (PM) adalah tumbuhan kaya fitoestrogen yang diuji untuk menentukan jika fitosteroidnya boleh 
menghalang sarkopenia terbergantung estrogen. Kesan PM pada tahap estrogen, kitaran estrous, ketoksikan, jisim otot, 
kekuatan dan ketahanan ekstensor digitorum longus (EDL) dan otot gastrocnemius tikus diovariektomi telah dikaji. Tikus 
Wistar betina dewasa dibahagikan kepada enam kumpulan: sham-dikawal (SHAM), ovariektomi (OVX) diberi air suling 
(PM0), OVX disuntik dengan 40 μg/kg estradiol benzoat (E40), OVX diberi ekstrak etanol PM pada dos 50 (PM50), 500 
(PM500) dan 1000 (PM1000) mg/kg selama 90 hari. Selepas rawatan dengan ketiga-tiga dos PM, tiada ketoksikan dikesan 
pada sistem hematopoietik dan fungsi hati manakala kumpulan E40 menunjukkan kesan toksik. Rawatan dengan 50 
dan 500 mg/kg PM tidak memberi kesan pada hipertrofi rahim dan tidak menyebabkan gangguan pada kitaran estrous 
berbanding rawatan dengan estrogen dan 1000 mg/kg rawatan PM yang menunjukkan kesan. Tahap estrogen, luas keratan 
rentas EDL dan kekuatan serta ketahanan gentian otot gastrocnemius berkurang secara signifikan dalam kumpulan PM0 
berbanding dengan kumpulan SHAM (p<0.05) yang meningkat dengan ketara dalam E40, PM50, PM500 dan PM1000 
berbanding dengan kumpulan PM0 (p<0.05). Ini menunjukkan bahawa aktiviti estrogenik PM mengurangkan atrofi otot 
dan membina kekuatan dan ketahanan otot. Oleh itu, 50 dan 500 mg/kg PM adalah sesuai untuk merawat sarcopenia 
bergantung estrogen kepada tikus diovariektomi.
Kata kunci: Estrogen;  ovariektomi; Pueraria mirifica; sarkopenia 
INTRODUCTION
A decrease of estrogen levels, especially in menopause, 
results in a decrease of muscle mass, strength and 
endurance, a condition known as estrogen dependent 
sarcopenia (Messier et al. 2011). The loss of muscle 
mass and strength can lead to an increased risk of 
falls and subsequent injuries, causing a decrease in 
the quality of life (Norshafarina et al. 2013). Estrogen 
replacement has been shown to improve skeletal muscle 
performance in ovariectomized rats (Bunratsami et al. 
2015) and postmenopausal women (Sipila et al. 2001). 
A previous study showed that estrogen replacement 
increased the muscle mass, strength and endurance in the 
extensor digitorum longus (EDL) and gastrocnemius in 
ovariectomized rats (Bunratsami et al. 2015). However, 
only a high dose of estrogen (40 mg/kg) improved both EDL 
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and gastrocnemius functions, but this had toxic effects on 
the uterus (Bunratsami et al. 2015). In addition, estrogen 
treatment can increase the risk of cancer especially breast 
cancer (Amin et al. 2015; Marsden 2002). Therefore, 
phytoestrogen supplementation has been considered to be 
an alternative treatment. Pueraria mirifica Airy Shaw & 
Suvatabandhu (Leguminosae) known in Thai as “Kwao 
Krua Kao”, is a Thai medical phytoestrogen-rich plant. 
It is a traditional medicine use by menopausal women 
for rejuvenation and estrogen replacement (Suntara 
1931). The plant tubers contain chemicals classified as 
phytoestrogens including isoflavones (Cherdshewasart et 
al. 2007a) and others such as miroestrol (Taylor et al. 1960) 
and deoxymiroestrol (Chansakaow et al. 2000). However, 
the isoflavonoids (daidzin, daidzein, genistin, genistein 
and puerarin) constitute the majority of the active chemical 
ingredients of the tubers (Cherdshewasart et al. 2007b). 
An estrogenic-like activity of Pueraria mirifica (PM) has 
been demonstrated on the reproductive organs of mammals 
and woman. An alcoholic extract of PM stimulated the 
proliferation of the epithelium of the vagina and uterus in 
female rats and woman (Pope et al. 1958; Malaivijitnond 
et al. 2004). Furthermore, PM has been demonstrated 
to provide other health benefits such as prevention of 
osteoporosis (Urasopon et al. 2008) and breast cancer 
(Cherdshewasart et al. 2007a). In the sarcopenia, atrophy 
of the predominantly type II fast twitch fibers was reported 
and led to a loss of muscle strength and power (Lang et al. 
2010). The EDL and gastrocnemius are type II fast twitch 
muscle fibers. In order to avoid the loss of skeletal muscle 
mass and improve muscle strength, high replacement doses 
of estrogen are required. This may result in an increased 
risk of cancer. Therefore, this study aimed to investigate 
the effect of PM on estrogen levels, reproductive organs, 
chemical toxicity, mass and strength of the EDL and 
gastrocnemius in an ovariectomized rat. The results may 
help to assess the possibility for using PM to replace 
estrogen therapy to prevent sarcopenia during menopause. 
MATERIALS AND METHODS
ANIMALS
Adult female Wistar rats, (12 weeks old, 250-300 g 
weight) were obtained from the Southern Laboratory 
Animal Facility, Prince of Songkla University, Thailand. 
The experimental protocols described in this study were 
approved by the Animal Ethics Committee of the Prince 
of Songkla University for the care and use of experimental 
animals (MOE 0521, 11/175). The rats were randomly 
divided into six groups (n=10 per group): sham-operated 
(SHAM), ovariectomized (OVX) fed with distilled water 
(PM0), OVX injected with 40 μg/kg estradiol benzoate 
(E40), OVX fed with ethanolic extract of Pueraria mirifica 
(PM) at doses of 50 (PM50), 500 (PM500) and 1000 
(PM1000) mg/kg for 90 days. The doses of treatment 
were modified from the work of Cherdshewasart (2003). 
Pueraria mirifica was a product from St. herb Cosmetics 
International Co./Ltd, Pathumthani, Thailand (Lot no: 
A55050501). The extract contained puerarin 31.75 mg, 
daidzin 5.81 mg, gonistin 7.22 mg, daidzein 15.75 mg and 
genistein 8.35 mg/100 g as determined by HPLC analysis.
EVALUATION OF THE ESTROUS CYCLE
A vaginal smear was performed daily for 5 days before the 
end of the experiment. The collected epithelial cells were 
stained with 0.5% methylene blue. The state of evaluation 
of the estrous cycle was determined according to the work 
of Wirakiat et al. (2012). The rats were in the stage of 
diestrus before ovariectomy, except for the SHAM group.
MEASUREMENT OF MUSCLE PERFORMANCE
At the end of the treatment, strength and endurance of the 
extensor digitorum longus (EDL) and the gastrocnemius 
were evaluated. The procedure for measurement was 
modified from the work of Bunratsami et al. (2015). Briefly, 
rats were anesthetized by an intraperitoneal injection of 
70 mg/kg thiopental. The EDL and gastrocnemius muscles 
were dissected and stimulated directly on the muscles using 
a bipolar electrode. The contractile force was converted to 
an analogue signal via a force transducer (Model 1030: AD 
Instruments, Australia). The signal was amplified using a 
Bridge Amplifier (Model 110, AD Instruments, Australia) 
and conveyed to a Chart program of the PowerLab system 
(Model 4/20; AD Instruments, Bella Vista, NSW, Australia) 
for converting into a digital signal. The data were stored 
for off line analysis.
SAMPLE PREPARATION
Blood samples were obtained from the orbital 
plexus to evaluate serum estradiol levels using an 
electrochemiluminescence immunoassay (ECIA) kit (LKE2 
1026, DPC, Gwyned, UK), modified from the work of 
Bunratsami et al. (2015) and a blood chemical analysis 
for a toxicity test. The EDL, gastrocnemius and uterus were 
removed and weighed.
MEASUREMENT OF MUSCLE FIBER SIZE
The protocol for measuring the cross-sectional area was 
modified from the work of Bunratsami et al. (2015). 
Briefly, serial 20 µm-thick frozen cross-sections of EDL and 
gastrocnemius were cut and stained with hematoxylin and 
eosin. The images of sections were captured with, a digital 
camera (DP50) Oylmpus, Tokyo, Japan. The area of the 
fiber of the EDL and gastrocnemius were measured using 
Image-pro Plus 6.0 analysis software (Media Cybernetics, 
Belnesda, MD, USA).
STATISTICAL ANALYSIS
Data are expressed as mean values ± standard error of the 
mean. The statistical evaluation of the data was performed 
using one-way ANOVA and a least significant difference 
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test (LSD) to determine any significant differences between 
the mean values. A P value of <0.05 was considered to be 
significant.
DISCUSSION
Our data have demonstrated that a reduction of the estrogen 
level (in the PM0 group) induced body weight gain and 
treatment with 17β-estradiol or 50 or 500 or 1000 mg/kg 
of Pueraria mirifica (PM50, 500, 1000) prevented the 
excess weight gain (Table 1). This correlated well with 
previous reports by Urasopon et al. (2008). The result 
indicated that the PM exhibited an estrogen-like effect on 
the rat body weight. The previous report found that 
Genistein, the most abundant isoflavone in soybeans, 
reduced food intake, body weight and fat pad weight in 
ovariectomized female mice (Park et al. 2009). This 
indicated that the Genistein present in the PM may have 
the same effect in decreasing the body weight as found for 
feeding soy beans. Our data also demonstrated that the 
reduction of estrogen levels (in the PM0 group) increased 
the atrophy of the uterus, whereas estrogen (40 mg/kg) and 
a 50, 500, or 1000 mg/kg of Pueraria mirifica replacement 
prevented atrophy of the uterus (Table 1). According to the 
work of Urasopon et al. (2008), treatment of 100 or 1000 
mg/kg B.W./day of PM for 90 days increased the uterine 
weight in the ovariectomized rats. Our data correlated well 
with that study. The data on the estrous cycle (Table 2) and 
estrogen levels (Figure 1) showed that in rats with a 
decreased estrogen level, only diestrus was found. A high 
level of serum estradiol was identified in the estrogen 
replacement group and only the proestrous and estrous 
were observed. In the high dose of PM replacement 
(PM1000) group, an increase of the estrogen level was 
observed similar to the SHAM group, the proestrous and 
estrous was identified as being similar to that of the 
estrogen replacement group. In contrast a low or medium 
dose of PM replacement (50, 500 mg/kg) increased the 
estrogen level less than that of the SHAM and the 3 stages 
of the estrogen cycle (proestrous, estrous and metestrous) 
were observed. These data have clearly demonstrated the 
estrogenic effects of Pueraria mirifica. Our data correlated 
well with the work of Malaivijitnond et al. (2004), when 
treatment with PM100 and 1000 led to an increase of uterine 
weight and vagina cornification, to indicate that PM can 
influence the female reproductive functions. A previous 
report by Pope et al. (1958) demonstrated that PM contained 
phytoestrogens that acted like estrogen in influencing 
vaginal cornification in ovariectomized rats. Puerarin is a 
major isoflavonoid component of the PM. It was found that 
treatment with 7.0 mg/kg B.W./day of puerarin for 140 
days increased vaginal cornification (Malaivijitnond et al. 
2010). It was also of interest, that treatment with PM 
increased the estrogen level. This finding indicated that 
the PM extract might stimulate hormone production from 
other sources. The hematological results (Table 3) 
TABLE 1. The rate of weight gain, uterine weight, EDL and gastrocnemius weights in all treatment groups
Parameters SHAM PM0 E40 PM50 PM500 PM1000
Weight gain (g/month) 6.70±0.41 13.46±0.96* 4.53±0.64+* 5.50±0.64+ 3.75±0.67+* 2.88±0.48+*
Uterine weight (g) 1.04±0.08 0.31±0.05* 1.12±0.05+ 0.79±0.07+* 0.86±0.09+* 0.88±0.05+
Uterine weight/body weight (×100) 0.39±0.03 0.10±0.02* 0.44±0.02+ 0.30±0.02+* 0.35±0.04+ 0.36±0.03+
EDL weight (g) 0.100±0.004 0.094±0.005 0.106±0.005 0.108±0.008 0.111±0.005+ 0.120±0.006+*
EDL weight/ body weight (×100) 0.038±0.002 0.030±0.001* 0.042±0.003+ 0.041±0.003+ 0.045±0.002+ 0.049±0.003+*
Gastrocnemius weight (g) 2.976±0.023 1.432±0.023* 2.699±0.050+* 2.847±0.104+ 2.574±0.048+* 2.611±0.047+*
Gastrocnemius weight/ 
body weight (×100)
1.092±0.025 0.902±0.025* 1.042±0.026+ 1.056±0.042+ 1.045±0.029+ 1.037±0.015+
*Significantly different from SHAM, P<0.05, + Significantly different from the PM0, p<0.05, n=10
TABLE 2. Identification of the stage of estrous cycle in all treatment groups
Groups Before treatment
the stage of estrous cycle
After treatment
the stage of estrous cycle
Proestrus Estrus Metestrus Diestrus Proestrus Estrus Metestrus Diestrus
SHAM + + + + + + + +
PM0 - - - + - - - +
E40 - - - + + + - -
PM50 - - - + + + + -
PM500 - - - + + + + -
PM1000 - - - + + + - -
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demonstrated that treatment with 40 mg/kg of estrogen for 
90 days caused a decrease of the erythrocytes (RBC) count, 
hemoglobin (Hb), % hematocrit (Hct) and increased SGPT 
levels. This indicated that a high dose of estrogen 
replacement may cause abnormalities of the hematopoietic 
system and liver function. In contrast, the treatment with 
50, 500 and 1000 mg/kg of Pueraria mirifica (PM) showed 
no significant alterations of the RBC count, Hb, Hct, platelet, 
SGOT and SGPT. This indicated that a Pueraria mirifica 
replacement had no toxicity to the hematopoietic system 
and liver functions. According to the work of Manosroi et 
al. (2004), treatment of 100 mg PM for 6 months appeared 
to be safe in rats. The treatment of 100, 1000 mg/kg B.W./
day for 90 days has also been shown to prevent bone loss 
in ovariectomized rats (Urasopon et al. 2008). Furthermore, 
Cherdshewasart (2003) has demonstrated that mice treated 
with the doses at 250, 500, 1000 or 2000 mg/kg B.W. for 
14 day caused no acute toxicity. Therefore, any doses lower 
than 2000 mg/kg B.W. is relatively non-toxic 
(Cherdshewasart 2003). This was consistent with a 
previous in vitro study that confirmed the non-mutagenic 
but reasonably antimutagenic activities this plant extracts 
(Cherdshewasart et al. 2009). As for the skeletal mass and 
strength, a decrease of estrogen levels resulted in a decrease 
of the EDL weight/body weight, gastrocnemius weight and 
gastrocnemius weight/body weight (Table 1). In contrast, 
estrogen and 50, 500, 1000 mg/kg B.W./day of PM 
replacements preserved the EDL weight/body weight, 
gastrocnemius weight and gastrocnemius weight/body 
weight (Table 1). This correlated with the size of the muscle 
fibers as observed using the light microscope (Figures 2 
and 3). A decrease of the cross-sectional areas of the EDL 
and gastrocnemius were observed in the PM0 group 
(Figures 2-4). This indicated that the reduction of estrogen 
level may induce muscle fiber atrophy. It was of interest, 
that replacements with estrogen and 50, 500 or 1000 mg/
kg B.W./day of Pueraria mirifica increased the cross-
sectional area of both the EDL and gastrocnemius (Figures 
2-4). This again indicated that PM exhibited an estrogen-
like effect on rat skeletal muscle mass. The effects of 
estrogen are mediated through two estrogen receptors: ERα 
and ERβ (Hall 2001). Both receptors were identified in the 
nucleus of the EDL and gastrocnemius muscle fibers 
(Bunratsami et al. 2015). The nucleus ERα and ERβ act as 
transcription factors involving protein synthesis in the 
muscle fiber. Thus, a decrease of estrogen level may result 
in a reduction of protein synthesis causing a decrease of 
muscle fiber size (atrophy). Previous work from Boonchird 
et al. (2010) reported that Pueraria mirifica (PM) bound to 
both estrogen receptors (ERα and ERβ) but more strongly 
to ERβ than to ERα. Thus, PM may bind with both of the 
estrogen receptors resulting in the induction of protein 
synthesis similar to that caused by estrogen. This may 
explain the effect of PM on preventing muscle atrophy of 
the EDL and gastrocnemius in the ovariectomized rats. The 
data of the muscle strength (the peak twitch tension, peak 
TABLE 3. Hematological tests in all treatment groups
Parameters SHAM PM0 E40 PM50 PM500 PM1000
RBC count (× 106)/μl  7.63±0.15 7.57±0.18 6.76±0.09* 7.26±0.19 7.32±0.18 7.18±0.14
Hb (g/dl) 13.86±0.10 13.54±0.15 12.01±0.23 12.44±0.29 12.49±0.24 12.28±0.16
Hct (%) 41.52±0.59 41.10±0.99 37.78±0.74* 39.74±1.06 41.08±0.74 39.28±0.79
Platelet count (× 103)/μl   693.80±34.25 744.30±76.05 789.50±31.31 741.20±46.50 788.90±37.64 791.50±47.48
SGOT (U/l) 174.80±11.07 164.80±6.69 190.40±9.15 185.20±16.35 160.7±7.23 159.9±13.13
SGPT (U/l) 94.80±6.11 96.50±3.36 147.90±9.41* 108.10±7.10 111.80±7.70 99.00±7.15
* Significantly different from the SHAM, P<0.05, n=10
FIGURE 1. The serum estradiol levels for all treatments: SHAM, PM0, E40, PM50, PM500 and PM1000 groups 
*Significantly different from the SHAM group (P<0.05), +Significantly different from the PM0 group, (P<0.05), (n=9)
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FIGURE 2. Cross-sectional micrographs of EDL in the SHAM (A), PM0 (B), E40(C), PM 
50 (D), PM 100 (E) and PM 1000 (F) groups
H&E staining, arrow; nucleus, Bars = 50 mm
tetanic tension), one-half relaxation time and endurance 
(time to fatigue) (Figures 5 and 6) demonstrated that a 
decrease of estrogen levels caused a decrease of the peak 
twitch tension, peak tetanic tension and time to fatigue and 
indicated the loss of muscle strength and endurance. In 
addition, a prolonged relaxation of EDL and gastrocnemius 
was found. This correlated well with the work of 
Bunratsami et al. (2015).  The loss of muscle strength was 
due to alterations in the myosin function, especially, the 
fraction of the strong-binding myosin during contraction 
and was not due to a decline in the contraction proteins 
such as actin and myosin (Moran et al. 2006). According 
to the work of Bunratsami et al. (2015) the prolonged 
relaxation was due to a decrease of the parvalbumin (PV) 
protein. PV acts as a relaxing factor in the fast-twitch 
skeletal muscle. The reduction of PV caused a prolonged 
relaxation resulting in prolonging the contraction relaxation 
cycle. In contrast the estrogen and 50, 500, 1000 mg of 
Pueraria mirifica (PM) increased the peak twitch tension, 
peak tetanic tension and time to fatigue (Figures 5 and 6). 
Furthermore, estrogen and PM also improved this prolonged 
relaxation. The estrogen replacement has been shown to 
improve a fraction of the myosin heads in the strong 
binding states during contraction (Moran et al. 2007) and 
increased the PV levels of the EDL and gastrocnemius 
(Bunratsami et al. 2015). This was one explanation for the 
mechanism of estrogen on enhancing the muscle strength 
and endurance. It was also of interest that, PM replacement 
improved the EDL and gastrocnemius strength and 
endurance. This may be due to its estrogenic effect. Thus 
it would be of interest to study the effect of PM on myosin 
function or PV levels to help to explain the mechanisms of 
PM that improve skeletal muscle strength and endurance. 
The data from this study have demonstrated that PM 
replacement is a potential approach to replace estrogen 
replacement for improving skeletal muscle atrophy and 
loss of strength and endurance especially in the estrogen 
dependent sarcopenia. Our data indicated that treatment 
with 40 mg/kg estrogen protected against skeletal muscle 
atrophy, encouraged a build-up of muscle strength and 
endurance, however, high level of serum estrogen was 
found. This may cause toxicity to the hematopoietic system 
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FIGURE 3. Cross-sectional micrographs of gastrocnemius in the SHAM (A), PM0 (B), 
E40(C), PM 50 (D), PM 100 (E) and PM 1000 (F) groups
H&E staining, arrow; nucleus, Bars = 50 mm 
FIGURE 4. The cross sectional area in all treatment groups: SHAM, PM0, E40, PM50, PM500 and PM1000 groups 
*Significantly different from the SHAM, P<0.05, n=10, + Significantly different from the PM0, P<0.05, n=10
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and liver function. Furthermore, it arrested the estrous 
cycle and may cause hypertrophy of the uterus. In contrast 
the treatment with 50 or 500 or 1000 mg/kg of Pueraria 
mirifica also prevented muscle atrophy, restored muscle 
strength and endurance. It showed no toxicity to the 
hematopoietic system and liver function. In addition, the 
serum estrogen was not too high thus the estrous cycle was 
almost identical to the natural system after treatment with 
PM. However, treatment with 1000 mg/kg of Pueraria 
mirifica, induced only two stages of the estrous cycle. It 
also prevented uterine atrophy but did not cause 
hypertrophy of the uterus. Therefore, the 50 or 500 mg/kg 
of Pueraria mirifica treatment may be a possible dose for 
treatment of estrogen dependent sarcopenia in 
ovariectomized rats. 
CONCLUSION
Treatment with 50, 500 or 1000 mg/kg of Pueraria mirifica 
for 90 days showed no toxicity, maintained the female rat 
reproductive system in ovariectomized rats in a natural 
manner, prevented muscle atrophy and restored muscle 
strength and endurance.
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